181 related articles for article (PubMed ID: 16767302)
21. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
Kim CH; Younossi ZM
Cleve Clin J Med; 2008 Oct; 75(10):721-8. PubMed ID: 18939388
[TBL] [Abstract][Full Text] [Related]
22. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift.
Nolan CJ; Prentki M
Diab Vasc Dis Res; 2019 Mar; 16(2):118-127. PubMed ID: 30770030
[TBL] [Abstract][Full Text] [Related]
23. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease.
Ioannou GN; Weiss NS; Boyko EJ; Kahn SE; Lee SP
Gastroenterology; 2005 Mar; 128(3):627-35. PubMed ID: 15810122
[TBL] [Abstract][Full Text] [Related]
24. Metabolic Consequences of Pediatric Obesity: A Review of Pathophysiology, Screening, and Treatment.
Gunaratne N; Deplewski D
Pediatr Ann; 2023 Feb; 52(2):e62-e67. PubMed ID: 36779885
[TBL] [Abstract][Full Text] [Related]
25. Insulin resistance in nonalcoholic fatty liver disease.
Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
[TBL] [Abstract][Full Text] [Related]
26. Polycystic ovary syndrome and type 2 diabetes mellitus.
De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
[TBL] [Abstract][Full Text] [Related]
27. [Hyperuricemia and uro-nephrological disorders].
Hurtes X; Meria P
Presse Med; 2011 Sep; 40(9 Pt 1):865-8. PubMed ID: 21684106
[TBL] [Abstract][Full Text] [Related]
28. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Cusi K
Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
[TBL] [Abstract][Full Text] [Related]
29. The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome.
Nestler JE; Clore JN; Blackard WG
Am J Obstet Gynecol; 1989 Nov; 161(5):1095-7. PubMed ID: 2686438
[TBL] [Abstract][Full Text] [Related]
30. Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells.
Kojima K; Shimada T; Nagareda Y; Watanabe M; Ishizaki J; Sai Y; Miyamoto K; Aburada M
Biol Pharm Bull; 2011; 34(10):1613-8. PubMed ID: 21963504
[TBL] [Abstract][Full Text] [Related]
31. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'.
Kincaid-Smith P
J Hypertens; 2004 Jun; 22(6):1051-5. PubMed ID: 15167435
[TBL] [Abstract][Full Text] [Related]
32. Race and the insulin resistance syndrome.
Kramer H; Dugas L; Rosas SE
Semin Nephrol; 2013 Sep; 33(5):457-67. PubMed ID: 24119851
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic fatty liver disease and metabolic syndrome: a concise review.
Streba LA; Cârstea D; Mitruţ P; Vere CC; Dragomir N; Streba CT
Rom J Morphol Embryol; 2008; 49(1):13-20. PubMed ID: 18273497
[TBL] [Abstract][Full Text] [Related]
34. Impact of hepatitis C virus therapy on metabolism and public health.
Shiffman ML; Gunn NT
Liver Int; 2017 Jan; 37 Suppl 1():13-18. PubMed ID: 28052632
[TBL] [Abstract][Full Text] [Related]
35. Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.
Torchen LC
Curr Diab Rep; 2017 Nov; 17(12):137. PubMed ID: 29128916
[TBL] [Abstract][Full Text] [Related]
36. Polycystic ovary syndrome and metabolic syndrome.
Ali AT
Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic fatty liver disease: Evolving paradigms.
Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
[TBL] [Abstract][Full Text] [Related]
38. Type 2 diabetes and the polycystic ovary syndrome.
Pelusi B; Gambineri A; Pasquali R
Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
[TBL] [Abstract][Full Text] [Related]
39. Polycystic Ovary Syndrome, A Complex Entity Involving Reproductive and Metabolic Impairments: A Systematic Review.
Amihăesei IC; Chelaru L; Lăcrămioara Zamfir C
Rev Med Chir Soc Med Nat Iasi; 2016; 120(4):755-9. PubMed ID: 30137754
[TBL] [Abstract][Full Text] [Related]
40. [Sleep and metabolic disorders].
Micić DD; Šumarac-Dumanović M; Šušić V; Pejković D; Polovina S
Glas Srp Akad Nauka Med; 2011; (51):5-25. PubMed ID: 22165724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
